27 results on '"Urinary Bladder Neoplasms/drug therapy"'
Search Results
2. A Rare Case of Granulomatous Pneumonitis Due to Intravesical BCG for Bladder Cancer
- Author
-
Vera Clérigo, Ana Castro, Teresa Mourato, and Conceição Gomes
- Subjects
BCG Vaccine ,Granuloma/chemically induced ,Pneumonia/chemically induced ,Urinary Bladder Neoplasms/drug therapy ,Medicine ,Medicine (General) ,R5-920 - Abstract
Granulomatous pneumonitis is a rare complication of bacillus Calmette-Guerin immunotherapy following intravesical administration of bacillus Calmette-Guerin. The authors present an unusual case of a 67-year-old man who developed mild and non-specific symptoms, following intravesical bacillus Calmette-Guerin instillations. Examinations revealed features of miliary tuberculosis and granuloma suggestive of mycobacterial infection. Anti-tuberculosis treatment resulted in a remarkable improvement in his symptoms and gradually upgrading of radiological appearance. The symptoms were less severe than some others described but this case provides evidence that, even in some cases, specific treatment may be necessary. We highlight the importance of recognizing miliary Mycobacterium bovis as a probable complication of bacillus Calmette-Guerin immunotherapy. The clinical disease course can be mild, despite extensive bilateral miliary nodules on primary presentation.
- Published
- 2019
- Full Text
- View/download PDF
3. Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
- Author
-
Emil Christensen, Iver Nordentoft, Karin Birkenkamp-Demtröder, Sara K. Elbæk, Sia V. Lindskrog, Ann Taber, Tine G. Andreasen, Trine Strandgaard, Michael Knudsen, Philippe Lamy, Mads Agerbæk, Jørgen B. Jensen, and Lars Dyrskjøt
- Subjects
Muscles/pathology ,Cancer Research ,Urinary Bladder Neoplasms/drug therapy ,Oncology ,Chemotherapy, Adjuvant ,DNA Mutational Analysis ,Neoadjuvant Therapy/adverse effects ,Humans ,Neoplasm Invasiveness/pathology ,Cystectomy ,Retrospective Studies - Abstract
Purpose: To investigate the use of plasma and urine DNA mutation analysis for predicting neoadjuvant chemotherapy (NAC) response and oncological outcome in patients with muscle-invasive bladder cancer. Experimental Design: Whole-exome sequencing of tumor and germline DNA was performed for 92 patients treated with NAC followed by radical cystectomy (RC). A custom NGS-panel capturing approximately 50 mutations per patient was designed and used to track mutated tumor DNA in plasma and urine. A total of 447 plasma samples, 281 urine supernatants, and 123 urine pellets collected before, during, and after treatment were analyzed. Patients were enrolled from 2013 to 2019, with a median follow-up time of 41.3 months after RC. Results: We identified tumor DNA before NAC in 89% of urine supernatants, 85% of urine pellets, and 43% of plasma samples. Tumor DNA levels were higher in urine supernatants and urine pellets compared with plasma samples (P < 0.001). In plasma, detection of circulating tumor DNA (ctDNA) before NAC was associated with a lower NAC response rate (P < 0.001). Detection of tumor DNA after NAC was associated with lower response rates in plasma, urine supernatant, and urine pellet (P < 0.001, P = 0.03, P = 0.002). Tumor DNA dynamics during NAC was predictive of NAC response and outcome in urine supernatant and plasma (P = 0.006 and P = 0.002). A combined measure from plasma and urine supernatant tumor DNA dynamics stratified patients by outcome (P = 0.003). Conclusions: Analysis of tumor DNA in plasma and urine samples both separately and combined has a potential to predict treatment response and outcome.
- Published
- 2023
4. DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial
- Author
-
Maria S. Lindgren, Erik Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, and Jørgen B. Jensen
- Subjects
Cancer Research ,Administration, Intravesical ,Neoplasm Recurrence, Local/drug therapy ,Treatment Outcome ,Oncology ,Antibiotics, Antineoplastic/therapeutic use ,Urinary Bladder Neoplasms/drug therapy ,Humans ,Neoplasm Invasiveness ,Mitomycin/adverse effects - Abstract
PURPOSE This study aimed to assess long-term follow-up after chemoresection with mitomycin (MMC), a nonsurgical treatment modality for recurrent nonmuscle invasive bladder cancer (NMIBC). At the time of recurrence, chemoresection has previously been shown to reduce the number of patients requiring a procedure (transurethral resection of bladder tumors [TURBT] or office biopsy) by more than 50%. This study investigated the number of patients requiring a procedure during initial treatment and 2-year follow-up in patients treated with short-term, intensive chemoresection with MMC compared with patients undergoing standard surgical treatment of recurrent NMIBC. METHODS A randomized, controlled trial was conducted in two urological departments in Denmark from January 2018 to August 2021. In total, 120 patients with a history of Ta low- or high-grade NMIBC were included upon recurrence. The intervention group received intravesical MMC (40 mg/40 mL) three times a week for 2 weeks and TURBT or office biopsy only if the response was incomplete. The control group received TURBT or office biopsy and 6 weekly adjuvant instillations. The primary outcome was the number of patients undergoing a procedure within 2 years from inclusion, which was compared between groups using the chi-squared test. Recurrence-free survival was analyzed using the Kaplan-Meier method. RESULTS Significantly fewer patients were in need of a procedure in the intervention group than in the control group: 71% (95% CI, 57 to 81) and 100% (95% CI, 94 to 100), P < .001. The 12-month recurrence-free survival was 36% (95% CI, 24 to 50) and 43% (95% CI, 30 to 56) in the intervention and control groups, respectively ( P = .5). CONCLUSION Short-term intensive chemoresection is an effective treatment strategy for recurrent NMIBC that leads to a reduced number of required procedures without compromising long-term oncological safety.
- Published
- 2023
5. Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies
- Author
-
Sonia Domingos-Pereira, Karthik Sathiyanadan, Lenka Polak, Jacques-Antoine Haefliger, Martina Schmittnaegel, Carola H. Ries, Patrice Jichlinski, Beat Roth, Laurent Derré, and Denise Nardelli-Haefliger
- Subjects
Inorganic Chemistry ,Organic Chemistry ,Animals ,Mice ,B7-H1 Antigen ,Urinary Bladder/pathology ,Urinary Bladder Neoplasms/drug therapy ,Urinary Bladder Neoplasms/metabolism ,Myeloid Cells/metabolism ,Chemokines/metabolism ,Cell Line, Tumor ,Tumor Microenvironment ,chemokine expression ,chemokine-targeting ,immune infiltration ,non-muscle-invasive bladder cancer ,orthotopic MB49-bladder model ,General Medicine ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy ,Catalysis ,Computer Science Applications - Abstract
Bacillus Calmette-Guérin (BCG) instillations for the treatment of non-muscle-invasive bladder cancer patients can result in significant side effects and treatment failure. Immune checkpoint blockade and/or decreasing tumor-infiltrating myeloid suppressor cells may be alternative or complementary treatments. Here, we have characterized immune cell infiltration and chemoattractant molecules in mouse orthotopic MB49 bladder tumors. Our data show a 100-fold increase in CD45 + immune cells from day 5 to day 9 tumors including T cells and mainly myeloid cells. Both monocytic myeloid-derived suppressor-cells (M-MDSC) and polymorphonuclear (PMN)-MDSC were strongly increased in day 9 tumors, with PMN-MDSC representing ca. 70% of the myeloid cells in day 12 tumors, while tumor associated macrophages (TAM) were only modestly increased. The kinetic of PD-L1 tumor expression correlated with published data from patients with PD-L1 expressing bladder tumors and with efficacy of anti-PD-1 treatment, further validating the orthotopic MB49 bladder-tumor model as suitable for designing novel therapeutic strategies. Comparison of chemoattractants expression during MB49 bladder tumors grow highlighted CCL8 and CCL12 (CCR2-ligands), CCL9 and CCL6 (CCR-1-ligands), CXCL2 and CXCL5 (CXCR2-ligands), CXCL12 (CXCR4-ligand) and antagonist of C5/C5a as potential targets to decrease myeloid suppressive cells. Data obtained with a single CCR2 inhibitor however showed that the complex chemokine crosstalk would require targeting multiple chemokines for anti-tumor efficacy.
- Published
- 2022
6. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
- Author
-
Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, Jean-Pascal Machiels, Jose Luis Perez Gracia, F Stephen Hodi, Alvaro Taus, Maria Martinez Garcia, Valentina Boni, Joseph P Eder, Navid Hafez, Ryan Sullivan, David Mcdermott, Stephane Champiat, Sandrine Aspeslagh, Catherine Terret, Anna-Maria Jegg, Wolfgang Jacob, Michael A Cannarile, Carola Ries, Konstanty Korski, Francesca Michielin, Randolph Christen, Galina Babitzki, Carl Watson, Georgina Meneses-Lorente, Martin Weisser, Dominik Rüttinger, Jean-Pierre Delord, Aurelien Marabelle, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Laboratory for Medical and Molecular Oncology, Clinical sciences, and Medical Oncology
- Subjects
Cancer Research ,Lung Neoplasms ,Carcinoma, Non-Small-Cell Lung/drug therapy ,T-Lymphocytes ,Immunology ,Antibodies, Monoclonal/adverse effects ,Antibodies, Monoclonal, Humanized ,Ligands ,Carcinoma, Non-Small-Cell Lung ,Immunology and Allergy ,Humans ,Melanoma/drug therapy ,Lung Neoplasms/drug therapy ,Immune Checkpoint Inhibitors ,Melanoma ,Fatigue ,Pharmacology ,Clinical Trials as Topic ,Urinary Bladder Neoplasms/drug therapy ,Macrophages ,Antibodies, Monoclonal ,Receptor Protein-Tyrosine Kinases ,Oncology ,Urinary Bladder Neoplasms ,Fatigue/chemically induced ,Molecular Medicine ,Drug Therapy, Combination ,Immunotherapy - Abstract
BackgroundThis phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with the programmed cell death-1 ligand (PD-L1)-blocking mAb atezolizumab in patients with advanced solid tumors naïve or experienced for immune checkpoint blockers (ICBs).MethodsEmactuzumab (500–1350 mg flat) and atezolizumab (1200 mg flat) were administered intravenously every 3 weeks. Dose escalation of emactuzumab was conducted using the 3+3 design up to the maximum tolerated dose (MTD) or optimal biological dose (OBD). Extension cohorts to evaluate pharmacodynamics and clinical activity were conducted in metastatic ICB-naive urothelial bladder cancer (UBC) and ICB-pretreated melanoma (MEL), non-small cell lung cancer (NSCLC) and UBC patients.ResultsOverall, 221 patients were treated. No MTD was reached and the OBD was determined at 1000 mg of emactuzumab in combination with 1200 mg of atezolizumab. Grade ≥3 treatment-related adverse events occurred in 25 (11.3%) patients of which fatigue and rash were the most common (14 patients (6.3%) each). The confirmed objective response rate (ORR) was 9.8% for ICB-naïve UBC, 12.5% for ICB-experienced NSCLC, 8.3% for ICB-experienced UBC and 5.6% for ICB-experienced MEL patients, respectively. Tumor biopsy analyses demonstrated increased activated CD8 +tumor infiltrating T lymphocytes (TILs) associated with clinical benefit in ICB-naïve UBC patients and less tumor-associated macrophage (TAM) reduction in ICB-experienced compared with ICB-naïve patients.ConclusionEmactuzumab in combination with atezolizumab demonstrated a manageable safety profile with increased fatigue and skin rash over usual atezolizumab monotherapy. A considerable ORR was particularly seen in ICB-experienced NSCLC patients. Increase ofCD8 +TILs under therapy appeared to be associated with persistence of a TAM subpopulation.
- Published
- 2022
7. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis
- Author
-
Jørgen Bjerggaard Jensen, Frederik Prip, Emil Christensen, Michael Knudsen, Philippe Lamy, Trine Line Hauge Okholm, Ann Taber, Torben Steiniche, Jakob Skou Pedersen, Sia Viborg Lindskrog, Karin Birkenkamp-Demtröder, Iver Nordentoft, Lars Dyrskjøt, and Mads Agerbæk
- Subjects
0301 basic medicine ,Genome instability ,Oncology ,Cisplatin/pharmacology ,Molecular biology ,CYSTECTOMY ,medicine.medical_treatment ,Programmed Cell Death 1 Receptor ,General Physics and Astronomy ,Proteomics ,Transcriptome ,NEOADJUVANT CHEMOTHERAPY ,0302 clinical medicine ,lcsh:Science ,Neoadjuvant therapy ,Cancer ,Epigenomics ,Multidisciplinary ,Molecular medicine ,Urinary Bladder Neoplasms/drug therapy ,GEMCITABINE PLUS CISPLATIN ,ASSOCIATION ,CLONAL EVOLUTION ,BRCA2 Protein/genetics ,Neoadjuvant Therapy ,Gene Expression Regulation, Neoplastic ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,DNA methylation ,Allelic Imbalance ,SURVIVAL ,SENSITIVITY ,medicine.drug ,medicine.medical_specialty ,CARCINOMA ,Urology ,Science ,SOMATIC ERCC2 MUTATIONS ,Genomics ,Context (language use) ,Article ,General Biochemistry, Genetics and Molecular Biology ,Genomic Instability ,03 medical and health sciences ,Medical research ,Drug Therapy ,Programmed Cell Death 1 Receptor/genetics ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,SIGNATURES ,Cisplatin ,BRCA2 Protein ,Bladder cancer ,business.industry ,General Chemistry ,DNA Methylation ,medicine.disease ,030104 developmental biology ,Urinary Bladder Neoplasms ,Gene Expression Regulation, Neoplastic/drug effects ,Mutation ,lcsh:Q ,business ,Biomarkers - Abstract
Overtreatment with cisplatin-based chemotherapy is a major issue in the management of muscle-invasive bladder cancer (MIBC), and currently none of the reported biomarkers for predicting response have been implemented in the clinic. Here we perform a comprehensive multi-omics analysis (genomics, transcriptomics, epigenomics and proteomics) of 300 MIBC patients treated with chemotherapy (neoadjuvant or first-line) to identify molecular changes associated with treatment response. DNA-based associations with response converge on genomic instability driven by a high number of chromosomal alterations, indels, signature 5 mutations and/or BRCA2 mutations. Expression data identifies the basal/squamous gene expression subtype to be associated with poor response. Immune cell infiltration and high PD-1 protein expression are associated with treatment response. Through integration of genomic and transcriptomic data, we demonstrate patient stratification to groups of low and high likelihood of cisplatin-based response. This could pave the way for future patient selection following validation in prospective clinical trials., There are currently only a few biomarkers to predict the response of muscle invasive bladder cancer to therapy. Here, the authors analyse 300 tumors using exome and RNA sequencing and find that tumors with a high degree of genomic instability and a non-basal/squamous gene expression subtype are most likely to respond to treatment.
- Published
- 2020
8. What have we learned after 30 years of BCG intravesical therapy for superficial bladder cancer?
- Author
-
Marcos Tobias-Machado, Marcos Adolfo Pereira Esteves, Eduardo Simões Starling, Antonio Carlos Lima Pompeo, and Eric Roger Wroclawski
- Subjects
Urinary bladder neoplasms/drug therapy ,Immunotherapy ,BCG vaccine/therapeutic use ,BCG vaccine/administration & dosage ,Medicine - Abstract
Objectives: To discuss the role of bacillus Calmette-Guérin (BCG) immunotherapy in the treatment of superficial bladder cancer after 30 years of clinical experience. Methods: Research on LILACS and PubMed databases, including 31 clinical studies with scientific relevance and importance in the decision-making process. Results: The BCG therapy with induction and maintenance therapy seems to be the best practice in tumors classified as high risk when compared to intravesical chemotherapy. In management of carcinoma in situ, BCG is undoubtedly the therapy of choice, presenting 84.4% of efficacy. As an adjuvant treatment to transurethral resection, there was a 31% reduction in recurrence confirmed in four out of five meta-analyses assessed. The reduction in progression, despite preliminary favorable evidence, still needs further studies to be confirmed. Conclusions: Intravesical BCG is an excellent therapeutic option in cases of carcinoma in situ and it is recommended as an adjuvant treatment in tumors with a high risk of recurrence and progression.
- Published
- 2009
9. Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma at a Tertiary Referral Center in Portugal.
- Author
-
Quaresma V, Marconi L, Jarimba R, Lima J, and Figueiredo A
- Subjects
- Humans, Portugal, Tertiary Care Centers, Immunotherapy, Carcinoma, Transitional Cell therapy, Carcinoma, Transitional Cell pathology, Urinary Bladder Neoplasms
- Published
- 2023
- Full Text
- View/download PDF
10. Immunothérapie dans le cancer de la vessie : mise à jour 2021 [Immunotherapy for bladder cancer in 2021]
- Author
-
Cisarovsky, C., Latifyan, S., Perrinjaquet, C., Berthold, D., and Orcurto, A.
- Subjects
Administration, Intravesical ,BCG Vaccine ,Humans ,Immunologic Factors/therapeutic use ,Immunotherapy ,Neoplasm Recurrence, Local ,Urinary Bladder Neoplasms/drug therapy - Abstract
Intravesical immunotherapy with Calmette-Guerin bacillus (BCG) have been used since decades for the treatment of non-muscle invasive bladder cancer and is a proof of principle that immunotherapy works for this malignancy. Since 2016, immune checkpoint inhibitors (ICI) demonstrated clinical benefits in locally advanced or metastatic bladder cancer, providing potentially durable tumor control in first line therapy or upon relapse after standard treatments. Ongoing clinical trials aim to demonstrate the efficiency of ICI for the treatment of localized disease.
- Published
- 2021
11. A Rare Case of Granulomatous Pneumonitis Due to Intravesical BCG for Bladder Cancer
- Author
-
Ana C. Meira Castro, Vera Clérigo, Conceição Gomes, and Teresa Mourato
- Subjects
medicine.medical_specialty ,Miliary tuberculosis ,medicine.medical_treatment ,lcsh:Medicine ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,Pneumonitis ,lcsh:R5-920 ,Mycobacterium bovis ,Bladder cancer ,Urinary Bladder Neoplasms/drug therapy ,biology ,business.industry ,Pneumonia/chemically induced ,lcsh:R ,General Medicine ,Immunotherapy ,medicine.disease ,biology.organism_classification ,Dermatology ,Granuloma/chemically induced ,030228 respiratory system ,030220 oncology & carcinogenesis ,Granuloma ,BCG Vaccine ,lcsh:Medicine (General) ,business ,Complication ,BCG vaccine - Abstract
Granulomatous pneumonitis is a rare complication of bacillus Calmette-Guerin immunotherapy following intravesical administration of bacillus Calmette-Guerin. The authors present an unusual case of a 67-year-old man who developed mild and non-specific symptoms, following intravesical bacillus Calmette-Guerin instillations. Examinations revealed features of miliary tuberculosis and granuloma suggestive of mycobacterial infection. Anti-tuberculosis treatment resulted in a remarkable improvement in his symptoms and gradually upgrading of radiological appearance. The symptoms were less severe than some others described but this case provides evidence that, even in some cases, specific treatment may be necessary. We highlight the importance of recognizing miliary Mycobacterium bovis as a probable complication of bacillus Calmette-Guerin immunotherapy. The clinical disease course can be mild, despite extensive bilateral miliary nodules on primary presentation.
- Published
- 2019
12. Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature
- Author
-
Gry Assam Taarnhøj, Helle Pappot, and Christoffer Johansen
- Subjects
Male ,Quality of life ,medicine.medical_specialty ,medicine.medical_treatment ,Urinary system ,Review ,Disease ,lcsh:Computer applications to medicine. Medical informatics ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Urothelial cancer ,Medicine ,Humans ,Chemotherapy ,030212 general & internal medicine ,Prospective Studies ,Bladder cancer ,Urinary Bladder Neoplasms/drug therapy ,business.industry ,030503 health policy & services ,Urinary diversion ,Public Health, Environmental and Occupational Health ,General Medicine ,Evidence-based medicine ,medicine.disease ,humanities ,Clinical trial ,Systematic review ,Quality of Life ,lcsh:R858-859.7 ,Female ,0305 other medical science ,business ,Muscle-invasive bladder cancer - Abstract
Background Previous quality of life (QoL) literature in bladder cancer (BC) patients has focused on finding the preferred urinary diversion while little is known about the QoL of patients in medical oncological treatment (MOT). We performed a systematic review to assess the existing literature on QoL in patients with muscle-invasive BC (MIBC) undergoing MOT. Methods A systematic search of Pubmed and Embase was performed. Inclusion criteria were studies containing QoL data for patients undergoing chemo- and/or radiotherapy. We extracted all QoL scorings at different time intervals and on the six most prevalent domains: overall QoL, urinary, bowel sexual symptoms, pain and fatigue. The study was carried out according to PRISMA guidelines for systematic reviews and GRADE was used to rate the quality of evidence from the included studies. Results Of 208 papers reviewed, 21 papers were included. Twenty-one different QoL instruments were applied. The only data on QoL during chemotherapy was from patients in clinical trials investigating new treatments. No studies were found for patients in neoadjuvant treatment. The level of evidence at each time point was graded as very low to moderate. From the studies included the overall QoL seemed inversely related to the organ-specific impairment from sexual and urinary symptoms and increased with decreasing organ-specific symptoms for long term survivors > 6 months after treatment. Conclusions Collection of data on QoL from patients with MIBC disease undergoing MOT has been sparse and diverse. The present data can act as a summary but prompts for more prospective collection of QoL data from BC patients. Electronic supplementary material The online version of this article (10.1186/s12955-018-1077-6) contains supplementary material, which is available to authorized users.
- Published
- 2019
13. Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands
- Author
-
Reesink, Daan J, van de Garde, Ewoudt M W, Peters, Bas J M, van der Nat, Paul B, Los, Maartje, Horenblas, Simon, van Melick, Harm H E, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology
- Subjects
Oncology ,Male ,Epidemiology ,medicine.medical_treatment ,030232 urology & nephrology ,lcsh:Medicine ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,80 and over ,Medicine ,Neoplasm Metastasis ,lcsh:Science ,Cancer ,Netherlands ,Aged, 80 and over ,Muscle Neoplasms ,Multidisciplinary ,Urinary Bladder Neoplasms/drug therapy ,Muscle invasive ,Middle Aged ,Muscle Neoplasms/drug therapy ,Neoadjuvant Therapy ,Survival Rate ,Treatment Outcome ,Outcomes research ,030220 oncology & carcinogenesis ,Female ,medicine.medical_specialty ,Treatment response ,Neoadjuvant Therapy/mortality ,Bladder ,Urology ,Article ,03 medical and health sciences ,Medical research ,Internal medicine ,Humans ,In patient ,Neoplasm Invasiveness ,Survival rate ,Aged ,Retrospective Studies ,Chemotherapy ,business.industry ,lcsh:R ,Induction chemotherapy ,Retrospective cohort study ,Metastatic bladder cancer ,Urinary Bladder Neoplasms ,lcsh:Q ,Antineoplastic Combined Chemotherapy Protocols/therapeutic use ,business ,Follow-Up Studies - Abstract
This retrospective study was performed to evaluate real-world oncological outcomes of patients treated with chemo-based therapy for muscle-invasive or metastatic bladder cancer (MIBC/mBC) and compare results to data from RCTs and other cohorts. Among 1578 patients diagnosed, 470 (30%) had MIBC/mBC. Median overall survival (mOS) for RC alone (47 months), first-line (13 months) and second-line (7 months) chemotherapy, and chemotherapy for recurrent disease (8 months) were similar to literature. Treatment with neoadjuvant and induction chemotherapy (NAIC) was only utilized in 9% of patients, and often in patients with poor disease status, resulting in a lower mOS compared to literature (35 and 20 months, respectively). Patients treated with chemotherapy had many adversities to treatment, with only 50%, 13%, 18% and 7% of patients in NAIC, first-line, salvage after RC, and second-line setting completing the full pre-planned chemotherapy treatment. Real-world data shows NAIC before RC is underutilized. Adversities during chemotherapy treatment are frequent, with many patients requiring dose reduction or early treatment termination, resulting in poor treatment response. Although treatment efficacy between RCTs and real-world patients is quite similar, there are large differences in baseline characteristics and treatment patterns. Possibly, results from retrospective studies on real-world data can deliver missing evidence on efficacy of chemotherapy treatment on older and ‘unfit’ patients.
- Published
- 2020
14. Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature
- Author
-
Taarnhøj, G A, Johansen, C, Pappot, H, Taarnhøj, G A, Johansen, C, and Pappot, H
- Abstract
BACKGROUND: Previous quality of life (QoL) literature in bladder cancer (BC) patients has focused on finding the preferred urinary diversion while little is known about the QoL of patients in medical oncological treatment (MOT). We performed a systematic review to assess the existing literature on QoL in patients with muscle-invasive BC (MIBC) undergoing MOT.METHODS: A systematic search of Pubmed and Embase was performed. Inclusion criteria were studies containing QoL data for patients undergoing chemo- and/or radiotherapy. We extracted all QoL scorings at different time intervals and on the six most prevalent domains: overall QoL, urinary, bowel sexual symptoms, pain and fatigue. The study was carried out according to PRISMA guidelines for systematic reviews and GRADE was used to rate the quality of evidence from the included studies.RESULTS: Of 208 papers reviewed, 21 papers were included. Twenty-one different QoL instruments were applied. The only data on QoL during chemotherapy was from patients in clinical trials investigating new treatments. No studies were found for patients in neoadjuvant treatment. The level of evidence at each time point was graded as very low to moderate. From the studies included the overall QoL seemed inversely related to the organ-specific impairment from sexual and urinary symptoms and increased with decreasing organ-specific symptoms for long term survivors > 6 months after treatment.CONCLUSIONS: Collection of data on QoL from patients with MIBC disease undergoing MOT has been sparse and diverse. The present data can act as a summary but prompts for more prospective collection of QoL data from BC patients.
- Published
- 2019
15. Carcinoma de células pequenas de bexiga.
- Author
-
Nagel Calado, Bruno, Goulart Maron, Paulo Eduardo, Vedovato, Bruno César, Zecchini Barrese, Tomas, de Carvalho Fernandes, Roni, and Cardenuto Perez, Marjo Deninson
- Abstract
Small cell carcinoma of the urinary bladder is an extremely aggressive and rare tumor. Even though small cell carcinoma most commonly arises from the lungs there are several reports of small cell carcinoma in extrapulmonary sites. Due to its low frequency there is no well-established management for this disease. We report the case of a 61 year-old man with small cell carcinoma of the bladder who underwent radical cystectomy following neoadjuvant chemotherapy. We also reviewed the literature for the optimal treatment strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study
- Author
-
Anders Ullén, H. von der Maase, Mads Agerbæk, and Helle Pappot
- Subjects
0301 basic medicine ,Oncology ,Male ,Organoplatinum Compounds ,medicine.medical_treatment ,chemistry.chemical_compound ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,Pharmacology (medical) ,Vinflunine ,Urinary Bladder Neoplasms/drug therapy ,Middle Aged ,Combined Modality Therapy ,Europe ,Pemetrexed ,030220 oncology & carcinogenesis ,Toxicity ,Female ,Urologic Neoplasms/drug therapy ,medicine.drug ,medicine.medical_specialty ,Urologic Neoplasms ,Anemia ,Vinblastine/administration & dosage ,Carcinoma, Transitional Cell/drug therapy ,Neutropenia ,Vinblastine ,Disease-Free Survival ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Organoplatinum Compounds/administration & dosage ,Adverse effect ,Aged ,Pharmacology ,Chemotherapy ,Carcinoma, Transitional Cell ,business.industry ,medicine.disease ,Surgery ,030104 developmental biology ,chemistry ,Urinary Bladder Neoplasms ,Antineoplastic Combined Chemotherapy Protocols/therapeutic use ,business ,Pemetrexed/administration & dosage ,Progressive disease - Abstract
Vinflunine is to date the only registered agent for second-line treatment of metastatic urothelial cell carcinoma (UCC) in Europe. However, the effect is modest. Pemetrexed has demonstrated some single-agent activity in this disease entity. In order to improve treatment possibilities for UCC patients, a phase I trial (VINTREX) was undertaken to assess the safety of vinflunine and pemetrexed in metastatic UCC patients. A dose escalation design was planned to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of a vinflunine/pemetrexed combination. Pemetrexed was added to vinflunine dosed at 280 mg/m2 on day 1 of a 21-day cycle. Three levels of pemetrexed were planned starting at 400 mg/m2. Four patients were enrolled with a mean age of 66 years and with a mean number of prior GC-cycles of 6,8. Two DLT's were observed at the lowest dose-level in cohort 1. One patient experienced grade 4 thrombocytopenia and a second demonstrated hepatobiliary toxicity grade 3 with an increase in alanine aminotransaminase. Most common grade 3 and 4 adverse events were anemia, thrombocytopenia and neutropenia. Three out of four patients received 3 cycles of pemetrexed and vinflunine, all had progressive disease. Based on these observations and due to protocol design, the study was interrupted at dose level 1 for safety reasons. The combined therapy of vinflunine (Javlor®, Pierre Fabre Pharma) and pemetrexed (Alimta®, Eli Lilly) is poorly tolerated in metastatic UCC patients. The combination cannot be recommended for further investigations in metastatic UCC. Vinflunine is to date the only registered agent for second-line treatment of metastatic urothelial cell carcinoma (UCC) in Europe. However, the effect is modest. Pemetrexed has demonstrated some single-agent activity in this disease entity. In order to improve treatment possibilities for UCC patients, a phase I trial (VINTREX) was undertaken to assess the safety of vinflunine and pemetrexed in metastatic UCC patients. A dose escalation design was planned to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of a vinflunine/pemetrexed combination. Pemetrexed was added to vinflunine dosed at 280 mg/m2 on day 1 of a 21-day cycle. Three levels of pemetrexed were planned starting at 400 mg/m2. Four patients were enrolled with a mean age of 66 years and with a mean number of prior GC-cycles of 6,8. Two DLT's were observed at the lowest dose-level in cohort 1. One patient experienced grade 4 thrombocytopenia and a second demonstrated hepatobiliary toxicity grade 3 with an increase in alanine aminotransaminase. Most common grade 3 and 4 adverse events were anemia, thrombocytopenia and neutropenia. Three out of four patients received 3 cycles of pemetrexed and vinflunine, all had progressive disease. Based on these observations and due to protocol design, the study was interrupted at dose level 1 for safety reasons. The combined therapy of vinflunine (Javlor®, Pierre Fabre Pharma) and pemetrexed (Alimta®, Eli Lilly) is poorly tolerated in metastatic UCC patients. The combination cannot be recommended for further investigations in metastatic UCC.
- Published
- 2017
17. Hexyl-aminolevulinate-mediated photodynamic therapy: How to spare normal urothelium. An in vitro approach
- Author
-
Patrice Jichlinski, Norbert Lange, Hubert van den Bergh, Celine Ritter-Schenk, Laurent Vaucher, and Pavel Kucera
- Subjects
Pathology ,medicine.medical_specialty ,Soft Tissue Injuries ,Cell Survival ,Swine ,medicine.medical_treatment ,Protoporphyrins ,Photodynamic therapy ,Dermatology ,In Vitro Techniques ,urologic and male genital diseases ,Reactive Oxygen Species/metabolism ,medicine ,Aminolevulinic Acid/analogs & derivatives/therapeutic use ,Animals ,Photosensitizer ,Photosensitizing Agents/pharmacology ,Urothelium ,Cell survival ,Protoporphyrins/pharmacology ,chemistry.chemical_classification ,Reactive oxygen species ,Mucous Membrane ,Photobleaching ,Photosensitizing Agents ,Urinary Bladder Neoplasms/drug therapy ,Chemistry ,Urothelium/drug effects/metabolism/pathology/radiation effects ,Aminolevulinic Acid ,female genital diseases and pregnancy complications ,In vitro ,Spectrometry, Fluorescence ,Urinary Bladder Neoplasms ,Photochemotherapy ,Microscopy, Electron, Scanning ,Superficial bladder cancer ,Cancer research ,Surgery ,Soft Tissue Injuries/prevention & control ,Reactive Oxygen Species - Abstract
Photodynamic therapy (PDT) of superficial bladder cancer may cause damages to the normal surrounding bladder wall. Prevention of these is important for bladder healing. We studied the influence of photosensitizer concentration, irradiation parameters, and production of reactive oxygen species (ROS) on the photodynamically induced damage in the porcine urothelium invitro. The aim was to determine the threshold conditions for the cell survival.Living porcine bladder mucosae were incubated with solution of hexylester of 5-aminolevulinic acid (HAL). The mucosae were irradiated with increasing doses and cell alterations were evaluated by scanning electron microscopy and by Sytox green fluorescence. The urothelial survival score was correlated with Protoporphyrin IX (PpIX) photobleaching and intracellular fluorescence of Rhodamine 123 reflecting the ROS production.The mortality ratio was dependent on PpIX concentration. After 3 hours of incubation, the threshold radiant exposures for blue light were 0.15 and 0.75 J/cm(2) (irradiance 30 and 75 mW/cm(2), respectively) and for white light 0.55 J/cm(2) (irradiance 30 mW/cm(2)). Photobleaching rate increased with decreasing irradiance. Interestingly, the DHR123/R123 reporter system correlated well with the threshold exposures under all conditions used.We have determined radiant exposures sparing half of normal urothelial cells. We propose that the use of low irradiance combined with systems reporting the ROS production in the irradiated tissue could improve the in vivo dosimetry and optimize the PDT.
- Published
- 2007
18. Small cell carcinoma of the bladder
- Author
-
Calado, Bruno Nagel, Maron, Paulo Eduardo Goulart, Vedovato, Bruno César, Barrese, Tomas Zecchini, Fernandes, Roni de Carvalho, and Perez, Marjo Deninson Cardenuto
- Subjects
Carcinoma de células pequenas/quimioterapia ,Relatos de casos ,Case reports ,Cistectomia/métodos ,Carcinoma ,Neoplasias da bexiga urinária/quimioterapia ,small cell/drug therapy ,Cystectomy/methods ,Urinary bladder neoplasms/drug therapy - Abstract
Small cell carcinoma of the urinary bladder is an extremely aggressive and rare tumor. Even though small cell carcinoma most commonly arises from the lungs there are several reports of small cell carcinoma in extrapulmonary sites. Due to its low frequency there is no well-established management for this disease. We report the case of a 61 year-old man with small cell carcinoma of the bladder who underwent radical cystectomy following neoadjuvant chemotherapy. We also reviewed the literature for the optimal treatment strategy. O carcinoma de células pequenas da bexiga urinária é um tumor extremamente agressivo e raro. Apesar desses tumores terem como sítio principal o pulmão, existem diversos relatos de carcinoma de pequenas células extrapulmonares. Pela baixa frequência, ainda não existe um tratamento bem estabelecido para essa neoplasia. Relatamos o caso de um homem de 61 anos de idade com carcinoma de células pequenas da bexiga urinária que foi submetido à quimioterapia neoadjuvante seguida de cistectomia radical. Fazemos ainda revisão na literatura em busca dos métodos de maior sucesso para o tratamento.
- Published
- 2015
19. A Rare Case of Granulomatous Pneumonitis Due to Intravesical BCG for Bladder Cancer.
- Author
-
Clérigo V, Castro A, Mourato T, and Gomes C
- Subjects
- Adjuvants, Immunologic administration & dosage, Administration, Intravesical, Aged, BCG Vaccine administration & dosage, Granuloma diagnostic imaging, Humans, Immunotherapy adverse effects, Male, Pneumonia diagnostic imaging, Rare Diseases diagnostic imaging, Tomography, X-Ray Computed, Tuberculosis, Miliary diagnosis, Tuberculosis, Miliary etiology, Adjuvants, Immunologic adverse effects, BCG Vaccine adverse effects, Granuloma etiology, Pneumonia etiology, Rare Diseases etiology, Urinary Bladder Neoplasms drug therapy
- Abstract
Granulomatous pneumonitis is a rare complication of bacillus Calmette-Guerin immunotherapy following intravesical administration of bacillus Calmette-Guerin. The authors present an unusual case of a 67-year-old man who developed mild and non-specific symptoms, following intravesical bacillus Calmette-Guerin instillations. Examinations revealed features of miliary tuberculosis and granuloma suggestive of mycobacterial infection. Anti-tuberculosis treatment resulted in a remarkable improvement in his symptoms and gradually upgrading of radiological appearance. The symptoms were less severe than some others described but this case provides evidence that, even in some cases, specific treatment may be necessary. We highlight the importance of recognizing miliary Mycobacterium bovis as a probable complication of bacillus Calmette-Guerin immunotherapy. The clinical disease course can be mild, despite extensive bilateral miliary nodules on primary presentation.
- Published
- 2019
- Full Text
- View/download PDF
20. Small cell carcinoma of the bladder
- Author
-
Bruno Nagel Calado, Paulo Eduardo Goulart Maron, Bruno César Vedovato, Tomas Zecchini Barrese, Roni de Carvalho Fernandes, and Marjo Deninson Cardenuto Perez
- Subjects
Urinary bladder neoplasms/drug therapy ,Carcinoma ,small cell/drug therapy ,Cystectomy/methods ,Case reports ,Medicine - Abstract
Small cell carcinoma of the urinary bladder is an extremely aggressive and rare tumor. Even though small cell carcinoma most commonly arises from the lungs there are several reports of small cell carcinoma in extrapulmonary sites. Due to its low frequency there is no well-established management for this disease. We report the case of a 61 year-old man with small cell carcinoma of the bladder who underwent radical cystectomy following neoadjuvant chemotherapy. We also reviewed the literature for the optimal treatment strategy.
- Full Text
- View/download PDF
21. The effect of intravesical chemotherapy on superficial urinary bladder cancer
- Author
-
Moriyama, Masatoshi, Kubota, Yoshinobu, Miura, Takeshi, Shuin, Taro, and Noguchi, Sumio
- Subjects
Male ,Urinary Bladder Neoplasms/drug therapy ,Urinary Bladder ,Carcinoma, Transitional Cell/drug therapy ,Doxorubicin/administration & dosage ,Middle Aged ,Drug Administration Schedule ,Injections ,Neoplasm Recurrence, Local/prevention & control ,Drug Evaluation ,Humans ,Bleomycin/administration & dosage ,Drug Therapy, Combination ,Female ,Antineoplastic Combined Chemotherapy Protocols/therapeutic use ,494.9 ,Carbazilquinone/administration & dosage ,Carcinoma, Papillary/drug therapy ,Aged ,Follow-Up Studies - Abstract
low grade, low stageの膀胱移行上皮癌患者59例に対してBLM, CQ, ADMの膀胱内注入療法を施行し57%の抗腫瘍効果を認めた.乳頭状腫瘍においては非乳頭状腫瘍におけるよりも高い抗腫瘍効果を認めた.3年以内の観察期間では, 注入療法施行群の再発率は34%であり, 注入非施行群に比してあきらかな再発予防効果を認めた.抗癌剤の膀胱内注入療法は, 表在性膀胱癌患者に対して有効な治療法の1つであると同時に再発予防効果もある, The effect of intravesical chemotherapy on superficial urinary bladder cancer was analysed. Fifty-nine patients with low-staged, low-grade bladder cancer were treated with intravesical instillation of three anticancer drugs (adriamycin, carbazilquinone and bleomycin). Complete response (CR) was observed in 15 out of 42 patients and partial response (PR) in 9 patients. Overall, a better response rate was observed with adriamycin and carbazilquinone than with bleomycin. Papillary tumors responded well to these intravesical chemotherapies compared to the non-papillary tumors . Intravesical recurrence of tumors was evaluated in 68 patients who received intravesical instillation of these three drugs after TUR of tumors. The actuarial recurrence rate of 68 patients was 11, 22 and 34% within 1, 2 and 3 years, respectively. These rates were significantly lower than that of TUR therapy alone. No serious side effect was seen in these patients. From these results, it is noted that intravesical chemotherapy is a useful approach for controlling superficial urinary bladder cancer.
- Published
- 1983
22. Clinical effect of UFT on urogenital tumors
- Author
-
Masuda, Fujio, Arai, Yoshikazu, Tashiro, Kazuya, and Machida, Toyohei
- Subjects
Male ,Urinary Bladder Neoplasms/drug therapy ,Carcinoma, Transitional Cell/drug therapy ,Drug Combinations/administration & dosage/adverse effects ,Middle Aged ,Bone and Bones/radionuclide imaging ,Kidney Neoplasms/drug therapy ,Adenocarcinoma/drug therapy ,Antineoplastic Combined Chemotherapy Protocols ,Tegafur/administration & dosage/adverse effects ,Drug Evaluation ,Humans ,Antineoplastic Agents/administration & dosage/adverse effects ,Female ,Prostatic Neoplasms/drug therapy ,Uracil/administration & dosage/adverse effects ,494.9 ,Aged - Abstract
UFTを腎細胞癌7例, 膀胱癌5例, 前立腺癌4例に投与した.1)抗腫瘍効果は, complete response (CR) 2例, partial response (PR) 2例, NC 12例で, PDはみとめず, 有効率は16例中4例であった.2)腎細胞癌では7例中CR 1例, PR 1例, 膀胱癌では5例中CR 1例, PR 1例であったが, 前立腺癌4例はすべてNCであった.3)副作用は, 600 mg/日投与6例中3例に, それぞれ食欲不振, 嘔気と嘔吐, 口内炎をみたが, 300 mg/日投与例に消化器症状はみなかった.4)骨髄機能の抑制や, 肝, 腎機能障害はみなかった, Clinical study of UFT which was a mixture of FT and uracil, was conducted on 16 patients with urogenital malignancies. Seven patients had renal cell carcinoma, 5 patients had bladder cancer and 4 patients had prostatic cancer. UFT was continuously administrated at doses of 300 mg or 600 mg per day. One of the patients with renal cell carcinoma and 1 of the patients with bladder cancer showed a complete response, and 1 patient with each cancer showed a partial response, but none of the 4 patients with prostatic cancer responded. In total, complete or partial responses were obtained in 4 of the 16 patients, given an effective rate of 25.0%. Concerning side effects, 3 of the 16 patients complained of anorexia, nausea and vomiting, and stomatitis, but no hepatic or renal disorders, or marrow depression was observed.
- Published
- 1984
23. 膀胱癌, 腎細胞癌に対するUFTの使用経験
- Author
-
Nakagami, Yoshizo, Lin, Tsaw Tung, Ito, Hiroshi, Hirasawa, Seiichi, Tannawa, Kunio, Fujioka, Yoshiaki, Ogawa, Hideya, Tanaka, Kyuhei, Yamada, Norimichi, Ishii, Yoji, and Hikima, Norio
- Subjects
Adult ,Male ,Uracil/administration & dosage ,Urinary Bladder Neoplasms/drug therapy ,Carcinoma, Transitional Cell/drug therapy ,Middle Aged ,urologic and male genital diseases ,Tegafur/administration & dosage ,Kidney Neoplasms/drug therapy ,Carcinoma, Renal Cell/drug therapy ,Humans ,Female ,Antineoplastic Combined Chemotherapy Protocols/therapeutic use ,494.9 ,Aged - Abstract
The safety of prolonged administration of UFT in which tegafur and uracil were mixed in a ratio of 1:4 in molar fraction was studied in 44 cases of bladder cancer and 10 cases of renal cell carcinoma. Daily doses of UFT were 300-600 mg, and average total doses administered were 102.0 g for bladder cancer and 116.6 g for renal cell carcinoma cases. Incidence of adverse effects were 25.0% in bladder cancer and 18.5% in renal cell carcinoma cases. Anorexia, nausea, vomiting and decrease in WBC were observed, but rates of having discontinued the administration of UFT were very low, being 9.1% in bladder cancer and 10.0% in renal cell carcinoma. Thus, UFT was considered to be tolerable during prolonged use in bladder cancer and renal cell carcinoma and also a drug in which more usefulness is expected in multidisciplinary treatments in future.
- Published
- 1987
24. Clinical application of tegafur suppositories for bladder tumor
- Author
-
Mishina, Teruo, Kobayashi, Tokuro, Maegawa, Mikio, Nakao, Masahiro, Nakagawa, Shuichi, and Watanabe, Hiroki
- Subjects
Adult ,Male ,Tegafur/administration & dosage/therapeutic use ,Urinary Bladder Neoplasms/drug therapy ,Carcinoma, Squamous Cell/drug therapy ,Suppositories ,Carcinoma, Transitional Cell/drug therapy ,Humans ,494.9 ,Middle Aged ,Aged ,Fluorouracil/analogs & derivatives ,Papilloma/drug therapy - Abstract
1)膀胱腫瘍20例(TaNxMo 8例, T1NxMo 5例, T2NxMo 3例, T3aNxMo 1例, T3bN2Mo 1例, T3bNxMo 1例, T4NxMo 1例)に750 mg Tegafur坐剤1個を連日23~161日(平均47.45日)を投与した.投与総量は17.25~120.75g(平均34.45g)であった.2)斉藤・小山班の固形がん化学療法直接効果判定基準にもとづき効果判定をおこなうと, CR0例(0%), PR5例(25%), MR3例(15%), NC 10例(50%), PD2例(10%)で, Response rate(奏効率)は25.0%であった.3) 20例中6例(30%)になんらかの副作用が認められた.すなわち全身倦怠感4例(20%), 食欲不振3例(15%), 下痢1例(5%), 浮腫1例(5%), 貧血2例(10%), GOT・GPT上昇1例(5%)および血小板減少1例(5%)が認められた.これら副作用も投薬の休止および保存的療法にて消褪した, A Tegafur suppository of 750 mg was administered daily to 20 patients with bladder tumors, whose ages ranged from 43 to 84 years (average age 63.7). Histological study revealed transitional cell papilloma in 6 cases, transitional cell carcinoma in 12 cases, squamous cell carcinoma in 1 case and malignant tumor with extensive necrosis in 1 case. The result of staging and grading was as follows: 8 cases of pTa, 5 cases of pT1, 9 cases of pT2, 1 case of pT3a, 2 cases of pT3b and 1 case of T4; an, 6 cases of G0, 6 cases of G1, 5 cases of G2, 2 cases of G3 and 1 case of unknown grade. According to Saitoh and Koyama's criteria, no cases showed complete response (0%), 5 cases partial response (25%), 3 cases minor response (15%), 10 cases no change (50%) and 2 cases progressive disease, making the total effective rate 25.0%. Some side effects were observed in 6 of the cases (30%): General malaise in 4 cases (20%), loss of appetite in 3 cases (15%), diarrhea in 1 case (5%), edema in 1 case (5%), anemia in 2 cases (10%), an elevation of both GOT and GPT in 1 case (5%) and thrombocytopenia in 1 case (5%). A recovery from these side effects was achieved after discontinuing the use of Tegafur suppositories.
- Published
- 1983
25. Study of combination chemotherapy with cytosine arabinoside in the intravesical treatment of superficial bladder tumors
- Author
-
Yoshida, Osamu, Miyakawa, Mieko, Watanabe, Hiroki, Mishina, Teruo, Kobayashi, Tokuro, Nakagawa, Kiyohide, Fukuyama, Takuo, Ogura, Keiji, Ueyama, Hidemaro, Itoh, Hitoshi, Hiratake, Yasuhiro, Fukuda, Toyohumi, Tabata, Yoshihisa, Furusawa, Taro, Okamura, Kazuhiro, Uchida, Mutsumi, Maekawa, Mikio, Kaiho, Hiroo, and Tanaka, Shigeki
- Subjects
Adult ,Male ,Urinary Bladder Neoplasms/drug therapy ,Mitomycin ,Urinary Bladder ,Middle Aged ,Carbazilquinone/administration & dosage/adverse effects ,Injections ,Drug Evaluation ,Humans ,Drug Therapy, Combination ,Female ,Zinostatin/administration & dosage/adverse effects ,494.9 ,Cytarabine/administration & dosage/adverse effects ,Aged ,Mitomycins/administration & dosage/adverse effects - Abstract
7機関より得た多発性表在性膀胱腫瘍111症例について, CAおよびCAとMMCまたはNCSまたはCQとの併用による治療効果を検討した.1) CA 400 mg投与29例の有効率は48.3%, CA 200 mgおよびMMC 20 mg併用投与25例の有効率は84.0%, CA 200 mgおよびNCS 4, 000 U併用28例は71.4%, CA 200 mgおよびNCS 6, 000 U併用22例は95.5%, CA 200 mgおよびCQ 10 mg併用7例は100%の有効率を示し, いずれの場合も併用療法がCA単独よりよい結果である.2)初発症例, 再発症例別にみた有効率にはほとんど差をみとめない.3)副作用はいずれも局所刺激症状で, 全身障害を示すものはない.CA単独の場合は3.4%, CAにCQを併用した場合がもっとも高く71.4%である.MMCとの併用では40.0%, NCS 4, 000 Uとの併用は3.6%, NCS 6, 000 Uとの併用の場合は22.7%であった, The effect of instillation therapy using CA alone or in combination with MMC, NCS or CQ was examined in 111 patients (92 males and 19 females, aged 32-87 years old with an average age of 66 years) with multiple superficial bladder tumors. The response rate of 29 patients given CA 400 mg alone was 48.3%, that of 25 patients given combination therapy of CA 200 mg and MMC 20 mg was 84.0%, that of 28 patients given combination therapy of CA 200 mg and NCS 4, 000 U was 71.4%, that of 22 patients given combination therapy of CA 200 mg and NCS 6, 000 U was 95.5% and that of 7 patients given combination therapy of CA 200 mg and CQ 10 mg was 100%. The response rates of the patients given any of the combination therapies were higher than that of the patients given CA alone. But because MMC, NCS and CQ were not administered singly, combination therapy cannot be concluded to be superior to single therapy. There was little difference between the response rate of primary cases and that of follow up cases. The side effects were all symptoms of local irritation, and were not indicative of systemic damage. Side effects were seen in 3.4%, 71.4%, 40.0% and 3.6% of the patients given CA alone, CA + CQ combination therapy, CA + MMC combination therapy and CA + NCS (4, 000) therapy, respectively, combination therapy of CA and CQ producing the highest percentage of side effects.
- Published
- 1983
26. Small cell carcinoma of the bladder
- Author
-
Bruno César Vedovato, Bruno Nagel Calado, Marjo Deninson Cardenuto Perez, Roni de Carvalho Fernandes, Paulo Eduardo Goulart Maron, and Tomas Zecchini Barrese
- Subjects
Male ,Relato De Caso ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,lcsh:Medicine ,Case Report ,Neoplasias da bexiga urinária/quimioterapia ,Disease ,Cystectomy/methods ,Small-cell carcinoma ,Cystectomy ,Carcinoma de células pequenas/quimioterapia ,Fatal Outcome ,Text mining ,medicine ,Carcinoma ,Humans ,small cell/drug therapy ,Carcinoma, Small Cell ,Chemotherapy ,Relatos de casos ,Urinary bladder ,Case reports ,business.industry ,Optimal treatment ,lcsh:R ,General Medicine ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Cistectomia/métodos ,Disease Progression ,business ,Urinary bladder neoplasms/drug therapy - Abstract
Small cell carcinoma of the urinary bladder is an extremely aggressive and rare tumor. Even though small cell carcinoma most commonly arises from the lungs there are several reports of small cell carcinoma in extrapulmonary sites. Due to its low frequency there is no well-established management for this disease. We report the case of a 61 year-old man with small cell carcinoma of the bladder who underwent radical cystectomy following neoadjuvant chemotherapy. We also reviewed the literature for the optimal treatment strategy. Keywords: Urinary bladder neoplasms/drug therapy; Carcinoma, small cell/drug therapy; Cystectomy/methods; Case reports
27. Cancer of the bladder. Combined 5-fluorouracil and cobalt-60 teletherapy.
- Author
-
Kaufman JJ, Langdon EA, Stein JJ, and Burt FB
- Subjects
- Combined Modality Therapy, Humans, Antimetabolites, Antimetabolites, Antineoplastic therapeutic use, Antineoplastic Agents, Carcinoma, Cobalt, Cobalt Radioisotopes therapeutic use, Fluorouracil therapeutic use, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms therapy
- Abstract
Three major attacks have previously been used on invasive carcinoma of the urinary bladder - surgical extirpation, irradiation therapy and chemotherapy. Of the chemotherapeutic agents, only systemic 5-fluorouracil has proved to possess merit. In a study of therapy with a judicious combination of these three therapeutic approaches in 32 cases, it appeared that tumor response was better and there were fewer major complications than with therapy by any one method. The report is preliminary, as the period of observation in not yet long enough.
- Published
- 1964
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.